BRIEF

on GENOWAY (EPA:ALGEN)

Promising development for the genOway Shanghai joint venture

Stock price chart of GENOWAY (EPA:ALGEN) showing fluctuations.

The biotechnology company genOway, listed on Euronext Growth, reports significant progress in the development of its joint venture in China. Created in October 2023, genOway Shanghai is asserting itself in the Chinese preclinical research market, the third largest in the world.

The joint venture quickly set up an operational production unit. In addition, it has obtained the necessary authorizations to import and produce immuno-oncology models. Currently, seven models are available in China, with a goal of 25 models soon.

The commercial structuring has also seen notable success with the hiring of three experienced salespeople and four immunologist technical salespeople. genOway Shanghai has already made its first sales and obtained referrals from large Chinese CROs.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all GENOWAY news